Trial Profile
Phase II Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (CRAD001CUS242T)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 May 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary)
- Indications Endometrial cancer; Ovarian cancer
- Focus Therapeutic Use
- 18 May 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
- 23 Jul 2014 New trial record